Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: The antiproliferative effect of first-line long acting somatostatin analogs (SSA) in advanced gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) was shown in the PROMID and the CLARINET trials. Efficacy data in pancreatic NETs (PanNETs) with Ki-67 ≥ 10% are limited.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Merola E
Authors: Merola E, Alonso Gordoa T, Zhang P, Al-Toubah T, Pelle E,
Keywords: Pancreatic NET, Somatostatin Analogs, Grade 2 and 3, Safety, Efficacy,
Introduction: Well-differentiated NET G3 show a longer clinical course than NEC G3, preliminary data indicate they respond poorly to platinum-based therapies.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Dal Buono A
Authors: Dal Buono A, Merola E, Delle Fave G, Wiedenmann B, Pavel M,
Keywords: well-differentiated, platinum, streptozotocin,
Introduction: ENETS requires Centers of Excellence to discuss all new gastroenteropancreatic neuroendocrine tumor (GEP-NET) patients in a multidisciplinary tumor board (MDT) but the true value of the MDT has never been assessed
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Zandee W
Authors: Zandee W, Merola E, de Mestier L, Klümpen H, Geboes K,
Keywords: Standard of Care, Multidisciplinary Tumor Board, Quality of Care,
Introduction: A proportion of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) referred to NEN expert centers need a histopathological revision.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author: Merola E
Authors: Merola E, Zandee W, de Mestier L, Klümpen H, Geboes K,
Keywords: neuroendocrine, NET referral centers, histopathological revision, patient management,
Introduction: Peritoneal carcinomatosis (PC) is present in 10-30% of digestive neuroendocrine neoplasms (DNENs), affecting prognosis and quality of life with recurrent abdominal pain and bowel obstruction
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: merola e
Authors: Merola E, Prasad V, Pascher A, Denecke T, Arsenic R,
Keywords: peritoneal carcinomatosis, neuroendocrine, bowel obstruction,